墨西哥血友病A患者的第八因子药理动力学
Jesús Hernandez-Juarez1, Guillermo Espejo-Godinez2, Julieta Espinoza-Islas2
1Consejo Nacional de Humanidades, Ciencias y Tecnologías-Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional Unidad Oaxaca, Instituto Politécnico Nacional, Santa Cruz Xoxocotlan, Oaxaca, Mexico; Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
在墨西哥重度血友病A患者中,XVIII因子的药理动力具有很高的变异性,表明过量服用. 个性化治疗至关重要,超越基于体重的治疗方案以获得最佳的XVIII因子治疗.
科学领域:
- 药理学
- 血液学
- 临床试验
背景情况:
- 严重的血友病A需要因子VIII替代治疗.
- 国际标准提倡使用药理动力学指导的VIII因子剂量.
- 第八因子的药物动力学分析不是墨西哥的标准做法.
研究的目的:
- 在墨西哥患有严重血友病A的患者中确定XVIII因子的药理动力学参数.
- 在该群体中确定因子VIII的基线药理学数据.
- 根据血友病A的个性化治疗策略.
主要方法:
- 对15名接受预防性因子VIII治疗的严重血友病A患者的分析.
- 在输液后多个时间点测量VIII因子活性.
- 使用WinNolin软件进行药物动力学建模 (单体和双体).
主要成果:
- 在患者中观察到因子VIII的显著变异性.
- 根据药理动力学概况,经常出现过量服用XVIII因子的证据.
- 一个双分支模型提供了一个更好的适合因子VIII的行为.
结论:
- 第八因子反应高度个性化,需要个性化治疗.
- 基于体重的剂量可能不是最佳的;建议以药理动力学为指导的治疗.
- 缺乏药理动力学数据可能会阻碍墨西哥采用先进的VIII因子疗法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics: Overview


